The costs associated with cancer drug prices have risen dramatically over the past 15 years, which is of concern to many top oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center ...
Jun 23, 2015
0
18
Metabolism experts are increasingly convinced that obesity and many of the pathogenic changes it entails, such as Metabolic Syndrome and type 2 diabetes, are a result of chronic inflammatory processes in fatty (adipose) tissue. ...
Jun 8, 2015
0
5
Leukemia cells from chronic myeloid leukemia patients, especially those in the advanced stage, lack the BRCA1 protein. Importantly, the protein is not present even if the patient carries the proper, unmutated gene responsible ...
Mar 26, 2015
0
11
This is the story of Abl and Src—two nearly identical protein kinases whose evolution may hold the key to unlocking new, highly specific cancer drugs.
Feb 19, 2015
1
107
The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically ...
Feb 9, 2015
0
27
Chronic myeloid leukemia develops when a gene mutates and causes an enzyme to become hyperactive, causing blood-forming stem cells in the bone marrow to grow rapidly into abnormal cells. The enzyme, Abl-kinase, is a member ...
Nov 17, 2014
0
0
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving the blood cancer chronic myeloid leukemia ...
Aug 20, 2014
0
0
(Medical Xpress)—Adelaide researchers are zeroing in on a promising new approach to killing off cancer cells in patients with leukaemia.
Jun 10, 2014
0
0
As a new therapeutic approach, Janus kinases are currently in the limelight of cancer research. The focus of interest is the protein JAK2. By inhibiting this protein one tries to cure chronic bone marrow diseases, such as ...
May 30, 2014
0
0
(HealthDay)—Ponatinib is active in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL), according to a study published online Nov. 1 in the New England Journal ...
Nov 5, 2013
0
0
